← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
151	151 Metagenomi Therapeutics MGX $31.7M	–	–	–	–
152	152 Maravai LifeSciences MRVI $1.02B	–	–	–	–
153	MSGR 153 DELISTED Direxion mRNA ETF MSGR	–	–	–	–
154	154 MaxCyte MXCT $133M	–	–	–	–
155	155 NewcelX Ltd NCEL $15.4M	–	–	–	–
156	156 DELISTED NKGen Biotech, Inc. Common Stock NKGN	–	–	–	–
157	157 Nkarta NKTX $139M	–	–	–	–
158	158 OmniAb OABI $675M	–	–	–	–
159	OBX 159 Obsidian Therapeutics OBX $762M	–	–	–	–
160	160 DELISTED Omega Therapeutics, Inc. Common Stock OMGA	–	–	–	–
161	161 DELISTED Singular Genomics Systems, Inc. Common Stock OMIC	–	–	–	–
162	162 DELISTED Orgenesis Inc. Common Stock ORGS	–	–	–	–
163	ORTX 163 DELISTED Orchard Therapeutics plc American Depositary Shares ORTX	–	–	–	–
164	164 Passage Bio PASG $12M	–	–	–	–
165	165 PepGen PEPG $175M	–	–	–	–
166	166 PharmaCyte Biotech PMCB $3.82M	–	–	–	–
167	167 Prime Medicine PRME $638M	–	–	–	–
168	168 ProKidney PROK $305M	–	–	–	–
169	169 Personalis PSNL $1.7B	–	–	–	–
170	170 DELISTED Poseida Therapeutics, Inc. Common Stock PSTX	–	–	–	–
171	171 Quantum-Si Incorporated QSI $274M	–	–	–	–
172	RCOR 172 DELISTED Renovacor, Inc. RCOR	–	–	–	–
173	173 Atrium Therapeutics RNA $133M	–	–	–	–
174	RUBY 174 DELISTED Rubius Therapeutics, Inc RUBY	–	–	–	–
175	175 Sana Biotechnology SANA $736M	–	–	–	–